A Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Injectafer® (Ferric Carboxymaltose) as Treatment for Heart Failure with Iron Deficiency.
Protocol Number: 1VIT15043
Principal Investigator: Christopher Malozzi, DO
Objective: The primary objective of this study is to determine the efficacy and safety of iron therapy using intravenous (IV) ferric carboxymaltose (FCM), relative to placebo, in the treatment of participants in heart failure with a reduced ejection fraction and with iron deficiency.
Kellie and I will work on the Research Board in the conference room. Please let me know if you want any other information.
A Randomized, Double-Blind, Placebo-Controlled study to assess the effects of bempedoic acid (ETC-1002) on the Occurrence of major cardiovascular events in patients with, or at high risk for, cardiovascular disease who are statin intolerant.
Protocol Number: 1002-043
Principal Investigator: Bassam Omar, MD, PhD
Objective: to determine if treatment with bempedoic acid (ETC-1002) versus placebo decreases the risk of cardiovascular events in patients who are statin intolerant.
Utilization of Ticagrelor in the Upstream Setting for Non-ST-Segment Elevation Acute Coronary Syndrome (UPSTREAM): An ED-Based Clinical Registry.
Protocol Number: NCT02271022
Principal Investigator: G. Mustafa Awan, MD
Objective: to address the data gap regarding the course of NSTEMI (Non-ST-Elevation Myocardial Infarction)between ED (Emergency Department) arrival and diagnostic angiography in detail, by characterizing and following the ED and peri-ED use of advanced OAP (Oral Anti-Platelet) agents.
Global Registry on Long-Term Oral Anti-thrombotic Treatment In Patients with Atrial Fibrillation
Protocol Number: 1160.129
Principal Investigator: Michael V. Cohen, MD
Objective: to investigate the patient characteristics influencing the choice of antithrombotic treatment for the prevention of stroke in non-valvular atrial fibrillation (AF) patients. To collect real world data on important outcome events of antithrombotic treatments for the prevention of stroke.
For information please contact Cherie Revere at (251) 471 - 7027
© 2018 USA Health